ORLADEYO net revenue of $124.2 million for Q4 2024 (+36.6 percent y-o-y) and $437.7 million for FY 2024 (+34.3 percent y-o-y)——FY 2025 ORLADEYO ...

Operator Good morning, and welcome to the BioCryst fourth-quarter 2024 earnings call. All participants will be in listen-only mode. [Operator instructions] Please note this event is being recorded. I ...

ORLADEYO net revenue of $124.2 million for Q4 2024 (+36.6 percent y-o-y) and $437.7 million for FY 2024 (+34.3 percent y-o-y)- -FY 2025 ORLADEYO net revenue guidance increased to between $535-$550 mil ...

DiaMedica Therapeutics Inc. , a clinical-stage biopharmaceutical company focused on acute ischemic stroke and preeclampsia, today announced the election of Daniel J. O'Connor to its Board of Directors ...

DiaMedica Therapeutics (DMAC) announced the peer-reviewed publication entitled: “Recombinant human tissue kallikrein-1 for treating acute ...

DiaMedica Therapeutics Inc. (Nasdaq: DMAC), a clinical-stage biopharmaceutical company focused on developing novel treatments for severe ischemic diseases, today announced the peer-reviewed ...

Astria advances innovative therapies for hereditary angioedema and atopic dermatitis. Strong cash position supports pivotal ...

BioCryst Pharmaceuticals, Inc. (Nasdaq: BCRX) today announced positive results from an interim analysis of the ongoing APeX-P ...

BioCryst Pharmaceuticals, Inc. (Nasdaq: BCRX) today announced that the company plans to present at the following conferences: ...

The article describes the mechanism of action of DM199 (rinvecalinase alfa), a recombinant form of human tissue kallikrein-1, and its scientific rationale in the Company’s ongoing Phase 2/3 ...

Astria Therapeutics, Inc. (Nasdaq:ATXS), a biopharmaceutical company focused on developing life-changing therapies for allergic and immunologic diseases, today announced that it will present three ...